Related Experiment Video
Updated: Jul 6, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Systemic BCG reactions after intravesical BCG therapy. A report of four cases]
Mohamed Sfaxi1, Houda Langar, Akrem Ouni
1Service d'Urologie, Hôpital Charles Nicolle, Tunis, Tunisie. momosfa@yahoo.fr
Abstract:
Local Bacillus Calmette-Guerin (BCG) immunotherapy is an effective and widely used treatment for superficial bladder carcinoma. Local side effects are frequent, whereas systemic side effects are rare, but more serious. We report four cases of systemic BCG reaction. Although uncommon, this infectious complication of BCG therapy should always be considered in the appropriate clinical setting. The best approach to minimize this complication is a strict compliance with precautions and a close and rigorous surveillance of this drug.
